Evaluation of Safety and Efficacy of Periprocedural Use of Rivaroxaban and Apixaban in Catheter Ablation for Atrial Fibrillation.

Trial Profile

Evaluation of Safety and Efficacy of Periprocedural Use of Rivaroxaban and Apixaban in Catheter Ablation for Atrial Fibrillation.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2015

At a glance

  • Drugs Apixaban (Primary) ; Rivaroxaban (Primary) ; Warfarin
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Dec 2015 Number of treatment arms changed from 2 to 3, according to University Hospital Medical Information Network - Japan record.
    • 20 Oct 2015 New trial record
    • 29 Aug 2015 Results published in 2015 Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top